These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7487638)

  • 1. High incidence of topical allergic reactions to 1% apraclonidine.
    Feibel RM
    Arch Ophthalmol; 1995 Dec; 113(12):1579-80. PubMed ID: 7487638
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions.
    Butler P; Mannschreck M; Lin S; Hwang I; Alvarado J
    Arch Ophthalmol; 1995 Mar; 113(3):293-6. PubMed ID: 7887842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
    Geyer O; Schmidt KG; Pianka P; Neudorfer M; Lazar M
    Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):149-52. PubMed ID: 10766284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic contact dermatitis from apraclonidine in eyedrops.
    Silvestre JF; Carnero L; Ramón R; Albares MP; Botella R
    Contact Dermatitis; 2001 Oct; 45(4):251. PubMed ID: 11683848
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
    Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
    Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to topical apraclonidine in children with glaucoma.
    Wright TM; Freedman SF
    J Glaucoma; 2009; 18(5):395-8. PubMed ID: 19525731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of apraclonidine on short-term outcome of glaucoma surgery.
    Azuara-Blanco A; Araujo SV; Lu DW; Lesk MR; Katz LJ; Spaeth GL
    J Glaucoma; 1996 Apr; 5(2):117-9. PubMed ID: 8795743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
    Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
    Williams GC; Orengo-Nania S; Gross RL
    J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of apraclonidine ophthalmic solution (iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
    Flach AJ
    Surv Ophthalmol; 1995; 40(1):84-5. PubMed ID: 8545811
    [No Abstract]   [Full Text] [Related]  

  • 12. Questions concerning the role of apraclonidine in the management of glaucoma.
    Robin AL
    Arch Ophthalmol; 1995 Jun; 113(6):712-4. PubMed ID: 7786208
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
    Gramer E; Busche S; Kampik A; Parsons D
    Graefes Arch Clin Exp Ophthalmol; 1995 Jan; 233(1):13-20. PubMed ID: 7721118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
    Stewart WC; Laibovitz R; Horwitz B; Stewart RH; Ritch R; Kottler M
    Arch Ophthalmol; 1996 Aug; 114(8):938-42. PubMed ID: 8694728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of alpha-agonists in glaucoma therapy.
    Robin AL
    Curr Opin Ophthalmol; 1997 Apr; 8(2):42-9. PubMed ID: 10168356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
    Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
    Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
    [No Abstract]   [Full Text] [Related]  

  • 18. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect and side effects of apraclonidine].
    Stewart WC
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):A7-13. PubMed ID: 8965469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.